Adamis Pharmaceuticals (NASDAQ: ADMP) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Adamis Pharmaceuticals to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations.
Institutional and Insider Ownership
16.7% of Adamis Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 9.6% of Adamis Pharmaceuticals shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Adamis Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals’ peers have a beta of 34.11, suggesting that their average stock price is 3,311% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Adamis Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamis Pharmaceuticals Competitors||873||3797||6772||181||2.54|
Adamis Pharmaceuticals presently has a consensus price target of $10.33, suggesting a potential upside of 119.86%. As a group, “Pharmaceuticals” companies have a potential upside of 26.89%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Adamis Pharmaceuticals is more favorable than its peers.
Valuation & Earnings
This table compares Adamis Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Adamis Pharmaceuticals||$6.47 million||-$19.43 million||N/A|
|Adamis Pharmaceuticals Competitors||$8.17 billion||$1.09 billion||118.76|
Adamis Pharmaceuticals’ peers have higher revenue and earnings than Adamis Pharmaceuticals.
This table compares Adamis Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamis Pharmaceuticals Competitors||-2,436.30%||-70.63%||-7.85%|
Adamis Pharmaceuticals peers beat Adamis Pharmaceuticals on 7 of the 12 factors compared.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.